This article presents the central issues discussed at the international conference Psychedelic-Assisted Therapy: Social and Legal Challenges, held at the Faculty of Law, University of Ljubljana, in June 2026. The conference focused on the therapeutic potential and safety of psychedelics, the importance of the social and cultural context in which they are used, and different neuroscientific, phenomenological and public health perspectives on their effects. The discussions also highlighted the gap between rapidly advancing research and the legal restrictions governing the use of psychedelics, particularly in Slovenia, where most of the substances discussed are classified as Schedule I of prohibited drugs, whose production, trade and possession are permitted only for scientific research and educational purposes, but not for use in medicine. The article therefore devotes particular attention to the legal status of individual psychedelics, comparative regulatory models, and the conditions governing research into them and their potential medical use. Shortly after the conference, the Ministry of Health proposed the reclassification of psilocybin from Schedule I to Schedule II of prohibited drugs, which would allow its use for medical purposes in approved clinical trials in Slovenia.
|